Publication Type : Conference Proceedings
Publisher : Elsevier
Source : Annals of Oncology, Volume 29, Issue suppl_9, 1 November 2018, mdy432.015, https://doi.org/10.1093/annonc/mdy432.015
Url : https://www.sciencedirect.com/science/article/pii/S092375341943130X?via%3Dihub
Campus : Kochi
School : School of Medicine
Year : 2018
Abstract : Background: Al Batrans fluouracil/leucovorin/oxaliplatin/docetaxel (FLOT) chemotherapy has been shown to significantly improve survival outcomes in patients with advanced gastric cancer, but there is no head to head comparison with the EOX regimen which has been shown to have the highest median OS in the REAL-2 study. The purpose of this study was to compare the safety and efficacy of these two regimens.
Cite this Research Publication : Srinivasalu V K, Subramaniam N, Jose W, Philip A, Pavithran K (2018) mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach. In: ESMO Asia 2018. Annals of Oncology, Volume 29, Issue suppl_9, 1 November 2018, mdy432.015, https://doi.org/10.1093/annonc/mdy432.015